Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells

Anti-Cancer Drugs

Volumn 22, Issue 6, 2011, Pages 507-518

  Burgeiro, Ana ^a,c   Gajate, Consuelo ^a,b   Dakir, El Habib ^a   Villa Pulgarín, Janny A ^a   Oliveira, Paulo J ^c   Mollinedo, Faustino ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

apoptosis; B RAF; berberine; extracellular signal regulated kinase signaling; melanoma; mitochondria; SK MEL 2

Indexed keywords

B RAF KINASE; BERBERINE; CASPASE 3; CASPASE 4; CASPASE 7; CASPASE 8; CASPASE 9; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BERBERINE; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROMES C; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; G1 PHASE; G2 PHASE; HUMANS; MELANOMA; MICROSCOPY, CONFOCAL; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS B-RAF; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 79958289658     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834438f6     Document Type: Article

References (55)

1. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008; 22:999-1012.
2. Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY. Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res 2007; 56:193-201.
3. Yan D, Jin C, Xiao XH, Dong XP. Antimicrobial properties of berberines alkaloids in Coptis chinensis Franch by microcalorimetry. J Biochem Biophys Methods 2008; 70:845-849.
4. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10:1344-1351. (Pubitemid 40022716)
5. Turner N, Li JY, Gosby A, To SW, Cheng Z, Miyoshi H, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008; 57:1414-1418.
6. Hayashi K, Minoda K, Nagaoka Y, Hayashi T, Uesato S. Antiviral activity of berberine and related compounds against human cytomegalovirus. Bioorg Med Chem Lett 2007; 17:1562-1564.
7. Kulkarni SK, Dhir A. Possible involvement of L-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur J Pharmacol 2007; 569:77-83. (Pubitemid 47175875)
8. Ho YT, Lu CC, Yang JS, Chiang JH, Li TC, Ip SW, et al. Berberine induced apoptosis via promoting the expression of caspase-8, -9 and -3, apoptosisinducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells. Anticancer Res 2009; 29:4063-4070.
9. Ho YT, Yang JS, Lu CC, Chiang JH, Li TC, Lin JJ, et al. Berberine inhibits human tongue squamous carcinoma cancer tumor growth in a murine xenograft model. Phytomedicine 2009; 16:887-890.
10. Tang F,Wang D, Duan C, Huang D,Wu Y, Chen Y, et al. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinasemediated Ezrin phosphorylation at threonine 567. J Biol Chem 2009; 284:27456-27466.
11. Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY, et al. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine 2009; 17:436-440.
12. Hur JM, Hyun MS, Lim SY, Lee WY, Kim D. The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem 2009; 107:955-964.
13. Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, et al. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol 2009; 34:1221-1230.
14. Liu Z, Liu Q, Xu B, Wu J, Guo C, Zhu F, et al. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat Res 2009; 662:75-83.
15. Katiyar SK, Meeran SM, Katiyar N, Akhtar S. p53 Cooperates berberineinduced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog 2009; 48:24-37.
16. Lin JP, Yang JS, Lee JH, Hsieh WT, Chung JG. Berberine induces cell cycle arrest and apoptosis in human gastric carcinoma SNU-5 cell line. World J Gastroenterol 2006; 12:21-28.
17. Choi MS, Yuk DY, Oh JH, Jung HY, Han SB, Moon DC et al. Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer Res 2008; 28:3777-3784.
18. Eom KS, Hong JM, Youn MJ, So HS, Park R, Kim JM, et al. Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol Pharm Bull 2008; 31:558-562. (Pubitemid 351500476)
19. Chen TC, Lai KC, Yang JS, Liao CL, Hsia TC, Chen GW, et al. Involvement of reactive oxygen species and caspase-dependent pathway in berberine-induced cell cycle arrest and apoptosis in C6 rat glioma cells. Int J Oncol 2009; 34:1681-1690.
20. Letasiova S, Jantova S, Cipak L, Muckova M. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett 2006; 239:254-262. (Pubitemid 43977860)
21. Serafim TL, Oliveira PJ, Sardao VA, Perkins E, Parke D, Holy J. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother Pharmacol 2008; 61:1007-1018. (Pubitemid 351423129)
22. Pereira GC, Branco AF, Matos JA, Pereira SL, Parke D, Perkins EL, et al. Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6- dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J Pharmacol Exp Ther 2007; 323:636-649. (Pubitemid 350005145)
23. Pereira CV, Machado NG, Oliveira PJ. Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicol Sci 2008; 105:408-417.
24. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355:51-65.
25. Burgeiro A, Mollinedo F, Oliveira PJ. Pharmacological handling of melanoma: the different roads to antagonize survival. J Theor Exp Pharmacol (in press).
26. Kwon KB, Park BH, Ryu DG. Chemotherapy through mitochondrial apoptosis using nutritional supplements and herbs: a brief overview. J Bioenerg Biomembr 2007; 39:31-34.
27. Mantena SK, Sharma SD, Katiyar SK. Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis 2006; 27:2018-2027. (Pubitemid 44530576)
28. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther 2006; 5:296-308.
29. Lin CC, Lin SY, Chung JG, Lin JP, Chen GW, Kao ST. Down-regulation of cyclin B1 and up-regulation of Wee1 by berberine promotes entry of leukemia cells into the G2/M-phase of the cell cycle. Anticancer Res 2006; 26:1097-1104.
30. Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-De Rojas A, Modolell M, et al. Involvement of mitochondria and caspase-3 in ET-18- OCH3-induced apoptosis of human leukemic cells. Int J Cancer 2000; 86:208-218. (Pubitemid 30180816)
31. Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95- and mitochondrialmediated mechanism. Clin Cancer Res 2003; 9:1535-1545. (Pubitemid 36418412)
32. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, Martinez-Dalmau R, et al. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res 1997; 57:1320-1328. (Pubitemid 27152558)
33. Ng FW, Nguyen M, Kwan T, Branton PE, Nicholson DW, Cromlish JA, et al. p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum. J Cell Biol 1997; 139:327-338. (Pubitemid 27459307)
34. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol. J Cell Biol 2003; 160:1115-1127. (Pubitemid 36443879)
35. Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, et al. Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. Proc Natl Acad Sci U S A 1997; 94:6939-6942.
36. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109:711-719. (Pubitemid 46105973)
37. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 2007; 11:447-460. (Pubitemid 46670078)
38. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005; 58:1163-1169. (Pubitemid 41566460)
39. Madhunapantula SV, Robertson GP. Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 2008; 68:5-8. (Pubitemid 351380097)
40. Caroppi P, Sinibaldi F, Fiorucci L, Santucci R. Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein. Curr Med Chem 2009; 16:4058-4065.
41. Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol 2010; 645:70-78.
42. Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, Zhang XD. Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis 2009; 30:197-204.
43. Kang BY, Chung SW, Cho D, Kim TS. Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid. Biochem Pharmacol 2002; 63:1901-1910. (Pubitemid 34603455)
44. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008; 68:5370-5379.
45. Muralimanoharan SB, Kunnumakkara AB, Shylesh B, Kulkarni KH, Haiyan X, Ming H, et al. Butanol fraction containing berberine or related compound from nexrutine inhibits NF-kappaB signaling and induces apoptosis in prostate cancer cells. Prostate 2009; 69:494-504.
46. Liu W, Zhang X, Liu P, Shen X, Lan T, Li W, et al. Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. Eur J Pharmacol 2010; 638:150-155.
47. Vrzal R, Zdarilova A, Ulrichova J, Blaha L, Giesy JP, Dvorak Z. Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IIE cells: biphasic effect on CYP1A1. Biochem Pharmacol 2005; 70:925-936. (Pubitemid 41138858)
48. Park KT, Mitchell KA, Huang G, Elferink CJ. The aryl hydrocarbon receptor predisposes hepatocytes to Fas-mediated apoptosis. Mol Pharmacol 2005; 67:612-622. (Pubitemid 40365308)
49. Marlowe JL, Fan Y, Chang X, Peng L, Knudsen ES, Xia Y, et al. The aryl hydrocarbon receptor binds to E2F1 and inhibits E2F1-induced apoptosis. Mol Biol Cell 2008; 19:3263-3271.
50. Reiners JJ Jr, Lee JY, Clift RE, Dudley DT, Myrand SP. PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase. Mol Pharmacol 1998; 53:438-445. (Pubitemid 28162865)
51. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005; 10:2986-3001. (Pubitemid 40910537)
52. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003; 63:756-759. (Pubitemid 36231971)
53. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954. (Pubitemid 34716871)
54. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62:6997-7000. (Pubitemid 35424092)
55. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang SY, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006; 66:11100-11105. (Pubitemid 46009933)